Well-dish and others continue to rank in, revising the profit and loss forecast for the fiscal year ending March 2025 from a deficit to a surplus.
Welldish <2901> is ranked (as of 13:32). Significantly up. After the previous trading session, the revenue forecast for the fiscal year ending in March 2025 was revised downward, but the profit forecast was revised upward from a loss to a profit, which seems to be attracting buyers. Operating profit is a profit of 0.08 billion yen. The previous forecast was a loss of 0.007 billion yen. Strengthening the food business, strengthening sales partnerships, successful sales of new products, etc. have contributed. Volume change rate top [November 1, 13:32 current] (last 5 days)
Japan Tobacco Inc. (JAPAY) Q3 2024 Earnings Call Transcript Summary
List of Conversion Stocks (Part 4) [List of Parabolic Signal Conversion Stocks]
Buy conversion stock list Market Code Stock name Closing price SARTSE main board <9663> Nagawa 6810 6550<9672>TOKYO KEIBA4175404537<9682>DTS3975378023<9757>Funai Institute24422361 NSD33123130<9889> JBCC HD 4430 3780<9948> Arkus
List of stocks with cleared clouds (Part 2) [Ichimoku Kinko Hyo: List of Stocks with Cleared Clouds]
Top breakthrough stocks list on the market Code Company Closing Price Leading Span A Leading Span B Tokyo Stock Exchange Prime Board 7211 Mitsubishi Motors 460 392.5 430 7296 FCC 2397 2385.5 2236 7414 Ono Construction 1503 1497 1488 7420 Satori Electric 1918 1903.75 1865 7483 Doshisha 2204 2164.5 2186.5
Asahi Kasei, TDK, Mitsui Chemicals, kddi corporation (1st day)
※Please note that the above calendar is subject to change depending on the company's circumstances.---------------------------------------November 1st (Friday)<2229>Calbee <2282>Nippon Ham<2296>Itoham Yonekyu Holdings <2349>NIID <2440>Gurunavi <2480>Sysmex<2551>MarsaInc <2730>Edion<27
Canon Inc-spons adr, 3Q operating profit increased by 14.4% to 296.6 billion yen.
Canon Inc-Spons ADR <7751> announced its third quarter financial results for the fiscal year ending December 2024, with revenue increasing by 7.3% year-on-year to 3 trillion 236.1 billion 11 million yen, operating profit increasing by 14.4% to 296.6 billion 38 million yen. The gross profit margin increased by 0.8 points from the same period last year to 47.8%, due to cost reductions and favorable product mix, with gross profit also increasing by 7.1% year-on-year to 516.4 billion yen. [Positive evaluation] Takeda Pharmaceuticals Mid-Term <4502> | <7735> S